Publications

Development of Protective Immunity in New Zealand White Rabbits challenged with Bacillus anthracis Spores and Treated with Antibiotics and Obiltoxaximab, a Monoclonal Antibody against Protective Antigen

January 2018

Animal-to-Human Dose Translation of Obiltoxaximab for Treatment of Inhalational Anthrax Under the US FDA Animal Rule

January 2017

Animal to Human Dose Translation under the Animal Rule- Obiltoxaximab (ETI-204) Case Study

February 2016

Poster at 2016 ASM Biodefense and Emerging Diseases Research Meeting Presentations, February 8-10, 2016

Safety. Pharmacokinetics, and Immunogenicity of Intramuscular (IM) Administration of Oblitoxaximab (ETI-204) to Healthy Humans

February 2016

Poster at 2016 ASM Biodefense and Emerging Diseases Research Meeting Presentations, February 8-10, 2016

The use of meta-analysis approach to demonstrate added benefit of Obiltoxaximab (ETI-204) in treatment of inhalational anthrax

February 2016

Poster at 2016 ASM Biodefense and Emerging Diseases Research Meeting Presentations, February 8-10, 2016

Pharmacokinetics and Tolerability of Obiltoxaximab: A Report of 5 Healthy Volunteer Studies

September 2016

Efficacy Projection of Obiltoxaximab for Treatment of Inhalational Anthrax across a Range of Disease Severity

October 2016

Obiltoxaximab Prevents Disseminated Vacillus anthracis Infection and Improves Survival during Pre-and Postexposure Prophylaxis in Animal Models of Inhalational Anthrax

October 2016